1. Home
  2. AIM vs ACXP Comparison

AIM vs ACXP Comparison

Compare AIM & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIM
  • ACXP
  • Stock Information
  • Founded
  • AIM 1966
  • ACXP 2017
  • Country
  • AIM United States
  • ACXP United States
  • Employees
  • AIM N/A
  • ACXP N/A
  • Industry
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • ACXP Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIM Health Care
  • ACXP Health Care
  • Exchange
  • AIM Nasdaq
  • ACXP Nasdaq
  • Market Cap
  • AIM 8.8M
  • ACXP 9.0M
  • IPO Year
  • AIM N/A
  • ACXP 2021
  • Fundamental
  • Price
  • AIM $0.12
  • ACXP $0.36
  • Analyst Decision
  • AIM Strong Buy
  • ACXP Strong Buy
  • Analyst Count
  • AIM 2
  • ACXP 1
  • Target Price
  • AIM $2.75
  • ACXP $12.00
  • AVG Volume (30 Days)
  • AIM 476.8K
  • ACXP 235.2K
  • Earning Date
  • AIM 03-27-2025
  • ACXP 05-13-2025
  • Dividend Yield
  • AIM N/A
  • ACXP N/A
  • EPS Growth
  • AIM N/A
  • ACXP N/A
  • EPS
  • AIM N/A
  • ACXP N/A
  • Revenue
  • AIM $170,000.00
  • ACXP N/A
  • Revenue This Year
  • AIM N/A
  • ACXP N/A
  • Revenue Next Year
  • AIM $1,693.10
  • ACXP N/A
  • P/E Ratio
  • AIM N/A
  • ACXP N/A
  • Revenue Growth
  • AIM N/A
  • ACXP N/A
  • 52 Week Low
  • AIM $0.11
  • ACXP $0.35
  • 52 Week High
  • AIM $0.62
  • ACXP $3.33
  • Technical
  • Relative Strength Index (RSI)
  • AIM 42.13
  • ACXP 26.25
  • Support Level
  • AIM $0.11
  • ACXP $0.40
  • Resistance Level
  • AIM $0.16
  • ACXP $0.45
  • Average True Range (ATR)
  • AIM 0.01
  • ACXP 0.03
  • MACD
  • AIM 0.00
  • ACXP 0.00
  • Stochastic Oscillator
  • AIM 5.00
  • ACXP 6.21

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Share on Social Networks: